EQS-News: Sartorius AG Supervisory Board extends appointment of board member Florian Funck
|
EQS-News: SARTORIUS AG
/ Key word(s): Personnel
Göttingen, Germany | April 24, 2026
Sartorius AG Supervisory Board extends appointment of board member Florian Funck The Supervisory Board of Sartorius AG resolved to extend the appointment of Dr. Florian Funck as Chief Financial Officer (CFO) and member of the Executive Board ahead of schedule to March 31, 2032. Funck (55) studied business administration at the University of Münster, where he also earned his doctorate. He subsequently spent more than two decades with the Haniel Group, most recently serving as CFO from 2011 to 2023. Funck was appointed to the Executive Board of Sartorius in April 2024; in this role, he is responsible for Finance & Controlling, IT & Process, Corporate Compliance, Internal Audit and Corporate Sourcing. In addition, Funck is a member of the Supervisory Board of Vonovia SE and an honorary professor at the University of Münster. The Executive Board of Sartorius AG also comprises Chairman and Chief Executive Officer Dr. Michael Grosse, who oversees Strategy, Human Resources, Corporate Research, Legal Affairs, and Communications & IR, as well as the two Heads of Division Dr. René Fáber (Bioprocess Solutions) and Dr. Alexandra Gatzemeyer (Lab Products & Services). Further Information CV of Florian Funck Financial calendar July 23, 2026 | Publication of half-year results for January to June 2026 October 22, 2026 | Publication of nine-month results January to September 2026 A profile of Sartorius Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe.
Visit our newsroom or follow Sartorius on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com Additional features: File: Sartorius AG Supervisory Board extends appointment of board member Florian Funck | Media Release File: Sartorius Member of the Executive Board Florian Funck | Photo 2026
24.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | SARTORIUS AG |
| Otto-Brenner-Straße 20 | |
| 37079 Göttingen | |
| Germany | |
| Phone: | +49.(0)551-308.0 |
| Fax: | +49.(0)551-308.3289 |
| E-mail: | info@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | DE0007165631, DE0007165607 |
| WKN: | 716563, 716560 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2312068 |
| End of News | EQS News Service |
|
|
2312068 24.04.2026 CET/CEST
Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL.
| Die wichtigsten Finanzdaten auf einen Blick | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Umsatzerlöse1 | 2.335,66 | 3.449,22 | 4.174,70 | 3.395,70 | 3.380,70 | 3.538,10 | 3.805,00 | |
| EBITDA1,2 | 636,70 | 1.134,26 | 1.410,40 | 962,70 | 945,30 | 1.051,60 | 1.165,00 | |
| EBITDA-Marge3 | 27,26 | 32,89 | 33,78 | 28,35 | 27,96 | 29,72 | 30,62 | |
| EBIT1,4 | 456,11 | 903,16 | 1.064,80 | 503,90 | 530,00 | 542,60 | 565,00 | |
| EBIT-Marge5 | 19,53 | 26,18 | 25,51 | 14,84 | 15,68 | 15,34 | 14,85 | |
| Jahresüberschuss1 | 299,56 | 426,98 | 913,10 | 290,60 | 137,40 | 230,40 | 250,00 | |
| Netto-Marge6 | 12,83 | 12,38 | 21,87 | 8,56 | 4,06 | 6,51 | 6,57 | |
| Cashflow1,7 | 511,53 | 865,81 | 734,20 | 853,60 | 976,00 | 837,00 | 860,00 | |
| Ergebnis je Aktie8 | 4,38 | 8,09 | 9,58 | 4,95 | 5,30 | 4,79 | 5,30 | |
| Dividende8 | 0,71 | 1,26 | 1,44 | 0,74 | 0,74 | 0,74 | 1,44 | |
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.
| INVESTOR-INFORMATIONEN | ||||||
| ©boersengefluester.de | ||||||
| Sartorius VZ | ||||||
| WKN | ISIN | Rechtsform | Börsenwert | IPO | Einschätzung | Plus Code |
| 716563 | DE0007165631 | AG | 14.743,87 Mio € | 10.07.1990 | Halten | 9F3FHV2Q+JW |
| KGV 2027e | KGV 10Y-Ø | BGFL-Ratio | Shiller-KGV | KBV | KCV | KUV |
| 36,47 | 40,14 | 0,91 | 50,31 | 6,17 | 19,57 | 4,17 |
|
Dividende '2023 in € |
Dividende '2024 in € |
Dividende '2025e in € |
Div.-Rendite '2025e in % |
| 0,74 | 0,74 | 0,74 | 0,34% |
| Hauptversammlung | Q1-Zahlen | Q2-Zahlen | Q3-Zahlen | Bilanz-PK |
| 26.03.2026 | 23.04.2026 | 23.07.2026 | 22.10.2026 | 16.02.2026 |
| Abstand 60-Tage-Linie | Abstand 200-Tage-Linie | Performance YtD | Kursveränderung 52 Wochen | IPO |
| -2,78% | -1,76% | -11,49% | -3,74% | +3.630,61% |
Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.
Kontakt
